05:42 EDT Sanofi (SNY) to acquire Blueprint Medicines (BPMC) for $129 per share in cash
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- M&A News: Sanofi Expands Cancer Drug Portfolio with $9.1B Blueprint Medicines Acquisition
- ‘Stay Invested’: Wells Fargo Suggests 2 Stocks to Ride the Market Recovery
- Blueprint Medicines’ Ayvakit Poised to Maintain Market Leadership Amidst Competitive Challenges
- Cautious Optimism: Blueprint Medicines’ Hold Rating Amid Mixed Growth Signals
- Blueprint Medicines: Strong Market Position and Growth Potential Justify Buy Rating with $135 Price Target